Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D(1) receptor positive allosteric modulator in patients with schizophrenia

ASP4345, a novel dopamine D(1) receptor positive allosteric modulator, is being evaluated for the treatment of cognitive impairment associated with schizophrenia (CIAS). This phase 1 multiple ascending-dose study (NCT02720263) assessed the safety, tolerability, and pharmacodynamics of ASP4345 in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Amit, Benner, Lauren, Wu, Ruishan, Gertsik, Lev, Maruff, Paul, Light, Gregory A., Uz, Tolga, Marek, Gerard J., Zhu, Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182805/
https://www.ncbi.nlm.nih.gov/pubmed/33203954
http://dx.doi.org/10.1038/s41386-020-00908-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182805/
https://www.ncbi.nlm.nih.gov/pubmed/33203954
http://dx.doi.org/10.1038/s41386-020-00908-0

Ejemplares similares